Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 6/20 | 0.44 |
| ▸ | BRD9 | Q9H8M2 | 4/20 | 0.44 |
| ▸ | TAF1 | P21675 | 1/20 | 0.44 |
| ▸ | CECR2 | Q9BXF3 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
| ▸ | OXTR | P30559 | 3/20 | 0.40 |
| ▸ | MTOR | P42345 | 5/20 | 0.39 |
| ▸ | METAP2 | P50579 | 1/20 | 0.38 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.38 |
| ▸ | FASN | P49327 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25852375 | 0.91 | METAP2 (0.42) | BRD4BRD9TAF1CECR2MTOR | |
| SCHEMBL25844189 | 0.85 | BRD4 (0.39) | BRD4BRD9TAF1CECR2KDM4E | |
| SCHEMBL25844196 | 0.85 | ACVR1 (0.41) | BRD4BRD9TAF1CECR2KDM4E | |
| SCHEMBL25844132 | 0.83 | BRD9 (0.45) | BRD4BRD9TAF1CECR2KDM4E | |
| SCHEMBL25091093 | 0.81 | METAP2 (0.43) | BRD4BRD9TAF1CECR2MTOR | |
| SCHEMBL23798962 | 0.79 | METAP2 (0.42) | BRD4BRD9TAF1CECR2MTOR | |
| SCHEMBL25844172 | 0.79 | BRD4 (0.43) | BRD4BRD9TAF1CECR2ALDH1A1 | |
| SCHEMBL23798711 | 0.78 | BRD4 (0.41) | BRD4BRD9TAF1CECR2ALDH1A1 | |
| SCHEMBL25852376 | 0.77 | BRD4 (0.39) | BRD4BRD9TAF1CECR2ALDH1A1 | |
| SCHEMBL25851626 | 0.77 | CYP3A4 (0.45) | BRD4BRD9TAF1CECR2MTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11691972-B2 | Compounds for targeted degradation of BRD9 | C4 THERAPEUTICS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11691972-B2 | Compounds for targeted degradation of BRD9 | BRD9, BRD1, BRWD1 | BRD4 17/4885BRD9 1/4885TAF1 868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.